Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation
UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
UCB scores Japanese approval for seizure therapy, Vimpat
July 5, 2016Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
Sanofi, Regeneron say cholesterol drug Praluent approved in Japan
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt
Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
Eisai launches cancer drug Lenvatinib in Mexico
July 4, 2016Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch
Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …
Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators
July 4, 2016Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial
Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …
Amgen says its blood cancer drug gets European backing for extended indication
July 4, 2016Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial
Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer
July 4, 2016Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study
Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …
Weekly Movers: Regulus, Nymox, Akers…
July 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks
Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
US doctors received $6.5 billion from drug, device firms in 2015
July 1, 2016Medical Communications, Research and Development, Sales and Marketing US, affordable care act, pharma, regulation
Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from …
UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI
July 1, 2016Business Services, Medical Communications, Sales and Marketing ABPI, Pharmacutical, corruption, disclosure, regulation
“We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association …
AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica
US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …
Shire says Phase II trial for rare eye condition in premature infants fails
July 1, 2016Medical Communications, Research and Development Shire, US FDA, drug trial, rare eye condition in infants
Shire plc (LSE: SHP) said its drug compound to treat a rare eye condition in infants failed mid-stage trials. The …
Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials
June 30, 2016Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer
German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …
Galena’s breast cancer immunotherapy fails in late-stage trials; shares plunge
June 30, 2016Research and Development, Sales and Marketing Galena Biopharma, Stock, breast cancer, drug trial
Shares in Galena Biopharma (Nasdaq: GALE) dropped over 80% after the company said an independent Data Monitoring Committee recommended that …
Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump
June 30, 2016Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer
Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …
Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication
June 30, 2016Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance
US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …
Shire says trial drug for ADHD shows positive results
June 30, 2016Research and Development, Sales and Marketing ADHD, Shire, US FDA, drug trial, regulation
UK drugmaker Shire plc (LSE: SHP) said its trial drug to treat Attention-Deficit/Hyperactivity Disorder (ADHD) showed positive topline results. Philip …
Regulus’ shares drop as FDA puts trials for hepatitis C drug on hold
June 29, 2016Research and Development, Sales and Marketing Regulus Therapeutics, US FDA, drug trial, hepatitis C virus, regulation
Shares in Regulus Therapeutics (Nasdaq: RGLS) plunged as much as 60% after the company said the US Food and Drug …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
